Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Retsevmo / selpercatinib for treating RET fusion-positive advanced non-small-cell lung cancer as of February 2025

MARA Rating Company December 16, 2025

Wegovy / semaglutide for managing overweight and obesity as of September 2023

MARA Rating Company December 16, 2025

Lokelma / sodium zirconium cyclosilicate for treating hyperkalaemia as of January 2022

MARA Rating Company December 16, 2025

Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy as of January 2022

MARA Rating Company December 16, 2025

Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea as of March 2022

MARA Rating Company December 16, 2025

Rubraca for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer as of September 2024

MARA Rating Company December 16, 2025

Rubraca / rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy as of April 2025

MARA Rating Company December 16, 2025

Ruxolitinib for treating polycythaemia vera as of October 2023

MARA Rating Company December 16, 2025

Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over as of April 2025

MARA Rating Company December 16, 2025

Trodelvy / sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies as of August 2022

MARA Rating Company December 16, 2025